(Q80496977)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577624%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

title

Analysis of risk factors for severe adverse effects of oral 5-fluorouracil S-1 in patients with advanced gastric cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577624%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577624%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author name string

Takeharu Yamanaka

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577624%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Shigemi Matsumoto

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577624%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Ryota Ishiwata

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577624%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Yoji Nagai

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577624%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Masanori Fukushima

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577624%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

publication date

25 June 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577624%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577624%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577624%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577624%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

129-134

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577624%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10120-007-0422-y

1 January 2020

exact match

0 references

cites work

Late phase II study of S-1 in patients with advanced head and neck cancer

1 reference

12 December 2020

[Phase I study of S-1. S-1 Study Group]

1 reference

12 December 2020

Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group

1 reference

12 December 2020

Sorafenib for the treatment of advanced renal cell carcinoma

1 reference

12 December 2020

Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats

1 reference

12 December 2020

Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma

1 reference

12 December 2020

Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators

1 reference

12 December 2020

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin

1 reference

12 December 2020

Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group

1 reference

12 December 2020

Prediction of creatinine clearance from serum creatinine

1 reference

12 December 2020

Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer

1 reference

12 December 2020

Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients

1 reference

12 December 2020

Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer

1 reference

12 December 2020

A phase II study of S-1 in patients with metastatic breast cancer--a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group

1 reference

12 December 2020